Patents by Inventor Hans Koll

Hans Koll has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies against insulin-like growth factor I receptor and uses thereof
    Publication number: 20080226635
    Abstract: An antibody binding to IGF-IR and being glycosylated with a sugar chain at Asn297, said antibody being characterized in that the amount of fucose within said sugar chain is between 20% and 50%, has improved properties in antitumor therapy.
    Type: Application
    Filed: December 11, 2007
    Publication date: September 18, 2008
    Inventors: Hans Koll, Klaus-Peter Kuenkele, Samuel Moser, Sylke Poehling
  • INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES
    Publication number: 20080171363
    Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.
    Type: Application
    Filed: August 14, 2007
    Publication date: July 17, 2008
    Inventors: Phillip A. Patten, Sridhar Viswanathan, Torben Lauesgaard Nissen, Anne Vogt, Harald Kropshofer, Ralf Schumacher, Stephan Fischer, Stefan Seeber, Adelbert Grossmann, Friederike Hesse, Andreas Schaubmar, Roberto Falkenstein, Hans Koll, Markus Dembowski
  • INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES
    Publication number: 20080076710
    Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.
    Type: Application
    Filed: May 4, 2007
    Publication date: March 27, 2008
    Inventors: Phillip Patten, Sridhar Viswanathan, Torben Nissen, Anne Vogt, Harald Kropshofer, Ralf Schumacher, Stephan Fischer, Stefan Seeber, Adelbert Grossmann, Friederike Hesse, Andreas Schaubmar, Roberto Falkenstein, Hans Koll, Markus Dembowski
  • INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES
    Publication number: 20080031853
    Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.
    Type: Application
    Filed: August 15, 2007
    Publication date: February 7, 2008
    Inventors: Phillip Patten, Sridhar Viswanathan, Torben Nissen, Anne Vogt, Harald Kropshofer, Ralf Schumacher, Stephan Fischer, Stefan Seeber, Adelbert Grossmann, Friederike Hesse, Andreas Schaubmar, Roberto Falkenstein, Hans Koll, Markus Dembowski
  • Interferon-alpha polypeptides and conjugates
    Patent number: 7318918
    Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.
    Type: Grant
    Filed: May 18, 2005
    Date of Patent: January 15, 2008
    Assignees: Maxygen, Inc., Roche Palo Alto LLC
    Inventors: Phillip A. Patten, Sridhar Viswanathan, Torben Lauesgaard Nissen, Anne Vogt, Harald Kropshofer, Ralf Schumacher, Stephan Fischer, Stefan Seeber, Andreas Schaubmar, Hans Koll
  • INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES
    Publication number: 20070225205
    Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.
    Type: Application
    Filed: September 14, 2006
    Publication date: September 27, 2007
    Applicants: MAXYGEN, INC., ROCHE PALO ALTO LLC
    Inventors: Phillip Patten, Sridhar Viswanathan, Torben Nissen, Anne Vogt, Harald Kropshofer, Ralf Schumacher, Stephan Fischer, Stefan Seeber, Adelbert Grossmann, Friederike Hesse, Andreas Schaubmar, Roberto Falkenstein, Hans Koll, Markus Dembowski
  • INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES
    Publication number: 20070225204
    Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.
    Type: Application
    Filed: September 14, 2006
    Publication date: September 27, 2007
    Applicants: MAXYGEN, INC., ROCHE PALO ALTO LLC
    Inventors: Phillip Patten, Sridhar Viswanathan, Torben Nissen, Anne Vogt, Harald Kropshofer, Ralf Schumacher, Stephan Fischer, Stefan Seeber, Adelbert Grossmann, Friederike Hesse, Andreas Schaubmar, Roberto Falkenstein, Hans Koll, Markus Dembowski
  • Methods for identifying human cell lines useful for endogenous gene activation, isolated human cell lines identified thereby, and uses thereof
    Patent number: 7214532
    Abstract: The invention concerns human cells which, due to an activation of the endogenous human EPO gene, are able to produce EPO in an adequate quantity and purity to enable a cost-effective production of human EPO as a pharmaceutical preparation. Furthermore the invention concerns a process for the production of such human EPO-producing cells, DNA constructs for the activation of the endogenous EPO gene in human cells as well as a process for the large-scale production of EPO in human cells.
    Type: Grant
    Filed: January 27, 2003
    Date of Patent: May 8, 2007
    Assignee: Roche Diagnostics, GmbH
    Inventors: Anne Stern, Michael Brandt, Konrad Honold, Johannes Auer, Hans Koll, Reinhard Franze, Ulrich Pessara
  • Preparation of erythropoietin by endogenous gene activation
    Patent number: 7186529
    Abstract: The invention relates to human cells which are capable, on the basis of an activation of the endogenous human EPO gene, of producing EPO in a sufficient amount and purity to make possible a cost-effective production of human EPO as a pharmaceutical preparation. The invention furthermore relates to a method for the preparation of such human EPO-producing cells, DNA constructs for the activation of the endogenous EPO in human cells, and a method for the large technical production of EPO in human cells.
    Type: Grant
    Filed: January 29, 2003
    Date of Patent: March 6, 2007
    Assignee: Roche Diagnostics GmbH
    Inventors: Anne Stern, Michael Brandt, Konrad Honold, Johannes Auer, Hans Koll
  • INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES
    Publication number: 20070025966
    Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.
    Type: Application
    Filed: September 13, 2006
    Publication date: February 1, 2007
    Applicants: MAXYGEN, INC., ROCHE PALO ALTO LLC
    Inventors: Phillip Patten, Sridhar Viswanathan, Torben Nissen, Anne Vogt, Harald Kropshofer, Ralf Schumacher, Stephan Fischer, Stefan Seeber, Adelbert Grossmann, Friederike Hesse, Andreas Schaubmar, Roberto Falkenstein, Hans Koll, Markus Dembowski
  • INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES
    Publication number: 20070020734
    Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.
    Type: Application
    Filed: September 13, 2006
    Publication date: January 25, 2007
    Applicants: MAXYGEN, INC., ROCHE PALO ALTO LLC
    Inventors: Phillip Patten, Sridhar Viswanathan, Torben Nissen, Anne Vogt, Harald Kropshofer, Ralf Schumacher, Stephan Fischer, Stefan Seeber, Adelbert Grossmann, Friederike Hesse, Andreas Schaubmar, Roberto Falkenstein, Hans Koll, Markus Dembowski
  • INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES
    Publication number: 20070020235
    Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.
    Type: Application
    Filed: September 13, 2006
    Publication date: January 25, 2007
    Applicants: MAXYGEN, INC., ROCHE PALO ALTO LLC
    Inventors: Phillip Patten, Sridhar Viswanathan, Torben Nissen, Anne Vogt, Harald Kropshofer, Ralf Schumacher, Stephan Fischer, Stefan Seeber, Adelbert Grossmann, Friederike Hesse, Andreas Schaubmar, Roberto Falkenstein, Hans Koll, Markus Dembowski
  • Erythropoietin with high specific activity
    Publication number: 20050288220
    Abstract: The invention concerns new EPO compositions with high specific activity which are characterized by a high proportion of N-acetyl-lactosamine units or/and tetraantennary branches in the carbohydrate structure. In addition the invention concerns a process for producing such EPO products.
    Type: Application
    Filed: August 9, 2005
    Publication date: December 29, 2005
    Inventors: Josef Burg, Karl-Heinz Sellinger, Anton Haselbeck, Hans Koll
  • Interferon-alpha polypeptides and conjugates
    Publication number: 20050266465
    Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.
    Type: Application
    Filed: May 18, 2005
    Publication date: December 1, 2005
    Inventors: Phillip Patten, Sridhar Viswanathan, Torben Nissen, Anne Vogt, Harald Kropshofer, Ralf Schumacher, Stephan Fischer, Stefan Seeber, Adelbert Grossmann, Friederike Hesse, Andreas Schaubmar, Roberto Falkenstein, Hans Koll, Markus Dembowski, Stephens Adam
  • Methods for identifying human cell lines useful for endogenous gene activation, isolated human cell lines identified thereby, and uses thereof
    Publication number: 20040203001
    Abstract: The invention concerns human cells which, due to an activation of the endogenous human EPO gene, are able to produce EPO in an adequate quantity and purity to enable a cost-effective production of human EPO as a pharmaceutical preparation. Furthermore the invention concerns a process for the production of such human EPO-producing cells, DNA constructs for the activation of the endogenous EPO gene in human cells as well as a process for the large-scale production of EPO in human cells.
    Type: Application
    Filed: January 27, 2003
    Publication date: October 14, 2004
    Inventors: Anne Stern, Michael Brandt, Konrad Honold, Johannes Auer, Hans Koll, Reinhard Franze, Ulrich Pessara
  • Methods for identifying tumors that are responsive to treatment with anti-ErbB2 antibodies
    Publication number: 20040106161
    Abstract: Tumors are identified as responsive to treatment with anti-HER2 antibodies by detecting the presence of a HER2/HER3 and/or HER2/HER1 protein complex or for HER2 phosphorylation in a sample of tumor cells. Patients suffering from a tumor comprising HER/2/HER1 and/or HER2/HER3 heterodimers and/or HER2 phosphorylation are treated with anti-HER2 antibodies, such as rhuMAb 2C4.
    Type: Application
    Filed: July 14, 2003
    Publication date: June 3, 2004
    Inventors: Birgit Bossenmaier, Hans-Joachim Muller, Hans Koll, Mark X. Sliwkowski, Stephen Michael Kelsey
  • Preparation of erythropoietin by endogenous gene activation
    Publication number: 20030166275
    Abstract: The invention relates to human cells which are capable, on the basis of an activation of the endogenous human EPO gene, of producing EPO in a sufficient amount and purity to make possible a cost-effective production of human EPO as a pharmaceutical preparation. The invention furthermore relates to a method for the preparation of such human EPO-producing cells, DNA constructs for the activation of the endogenous EPO in human cells, and a method for the large technical production of EPO in human cells.
    Type: Application
    Filed: January 29, 2003
    Publication date: September 4, 2003
    Inventors: Anne Stern, Michael Brandt, Konrad Honold, Johannes Auer, Hans Koll
  • Methods for identifying human cell lines useful for endogenous gene activation isolated human cell lines identified thereby, and uses thereof
    Patent number: 6555373
    Abstract: The invention concerns human cells which, due to an activation of the endogenous human EPO gene, are able to produce EPO in an adequate quantity and purity to enable a cost-effective production of human EPO as a pharmaceutical preparation. Furthermore the invention concerns a process for the production of such human EPO-producing cells, DNA constructs for the activation of the endogenous EPO gene in human cells as well as a process for the large-scale production of EPO in human cells.
    Type: Grant
    Filed: June 30, 2000
    Date of Patent: April 29, 2003
    Assignee: Roche Diagnostics GmbH
    Inventors: Anne Stern, Michael Brandt, Konrad Honold, Johannes Auer, Hans Koll, Reinhard Franze, Ulrich Pessara
  • Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof
    Patent number: 6548296
    Abstract: The invention concerns human cells which, due to an activation of the endogenous human EPO gene, are able to produce EPO in an adequate quantity and purity to enable a cost-effective production of human EPO as a pharmaceutical preparation. Furthermore the invention concerns a process for the production of such human EPO-producing cells, DNA constructs for the activation of the endogenous EPO gene in human cells as well as a process for the large-scale production of EPO in human cells.
    Type: Grant
    Filed: July 10, 1998
    Date of Patent: April 15, 2003
    Assignee: Roche Diagnostics GmbH
    Inventors: Anne Stern, Michael Brandt, Konrad Honold, Johannes Auer, Hans Koll, Reinhard Franze, Ulrich Pessara
  • Preparation of erythropoietin by endogenous gene activation
    Patent number: 6544748
    Abstract: The invention relates to human cells which are capable, on the basis of an activation of the endogenous human EPO gene, of producing EPO in a sufficient amount and purity to make possible a cost-effective production of human EPO as a pharmaceutical preparation. The invention furthermore relates to a method for the preparation of such human EPO-producing cells, DNA constructs for the activation of the endogenous EPO in human cells, and a method for the large technical production of EPO in human cells.
    Type: Grant
    Filed: November 2, 2001
    Date of Patent: April 8, 2003
    Assignee: Roche Diagnostics GmbH
    Inventors: Anne Stern, Michael Brandt, Konrad Honold, Johannes Auer, Hans Koll